Effects of branched-chain amino acid consumption in association with omega-3 in clinical-nutritional, cardiorespiratory, metabolic parameters and quality of life in cachectic patients

Not Applicable

Recruiting

• Conditions: Cachexia, cancer, heart failure; C23.888.144.243.963.500.500; C14.280.434

• Registration Number: RBR-943djg
• Lead Sponsor: niversidade Federal do Maranhão - UFMA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-08-16
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Individuals over 18 years of age; pre-cachexia; cachexia; stability (absence of modifications in drug therapy in the last 6 weeks or hospitalizations in the last 3 months).

Exclusion Criteria

Individuals over 85 years of age; refractory cachexia (pre-terminal state, life expectancy <3 months, intense catabolism, lack of response to drug therapy); palliative care; use of branded step; water imbalance; allergy to nutritional composition of supplements; withdrawal of consent; adherence to intervention of less than 75%; refusal of proposed supplementation; worsening after intervention.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effectiveness of branched chain amino acid supplementation in association with omega 3 in improving clinical, nutritional, cardiorespiratory, metabolic parameters and quality of life in cachectic patients.

Secondary Outcome Measures

Name	Time	Method
Recovery of anthropometric measures (weight, BMI, CB, PCT and AMB) and body composition (muscle, fat, cellular mass) after the intervention;<br>Reduction of the frequency of sarcopenic patients after the intervention;<br>Improvement in heart rate measurements, blood pressure control (SBP and DBP), as well as biochemical parameters (fasting glycemia, lipidogram, blood count, IL-1, IL-6, TNF-alpha, insulinemia, HOMA index, US, plasma adiponectin, albumin, pro-n-terminal natriuretic peptide) after the intervention;<br>Improvement of functional capacity (IPAQ and TC6 classification) after the intervention;<br>Improvement of muscle strength (dynamometry) after the intervention;<br>Improved quality of life (Minnesota Living with Heart Failure Questionnaire and EORTC Quality of Life Questionnarie) after the intervention;<br>Associate the intervention led to the reduction of the number of readmissions in less than 30 days and death of those evaluated.